Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics Corp (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
$2.21
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.21
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$1.65 - $51.75
Previous CloseN/A
Volume52.80K
Average Volume (3M)54.18K
Market Cap
$6.60M
Enterprise Value-$3.39M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$485.00K
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Mar 24, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding3,126,642
10 Day Avg. Volume61,353
30 Day Avg. Volume54,180
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)-47.15
Price to Sales (P/S)0.00
P/FCF Ratio-22.34
Enterprise Value/Market Cap-0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit484.71
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$9.00Price Target Upside307.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressSilexion announced it submitted the regulatory application in Israel for its Phase 2/3 trial of SIL-204 in patients with locally advanced pancreatic cancer, highlighting progress in clinical development.
KRAS Inhibition PotentialSIL-204 has now demonstrated anti-tumor activity in 5 different KRAS mutated cancer types and inhibition across 8 different KRAS mutations, which positively supports the in-human clinical potential of SIL-204 and increases the overall market opportunity.
Market OpportunityThere remains a significant unmet need in pancreatic cancer, presenting a significant market opportunity for SIL-204.
Bears Say
Financial ChallengesCash should be sufficient to initiate the Phase 2/3 trial, but additional capital will likely be required to complete the trial.
Price Target AdjustmentThe 12-month price target has been lowered to $12.00 from $24.00 due to the inclusion of additional shares from the capital raise.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics Corp’s price range in the past 12 months?
Silexion Therapeutics Corp lowest stock price was $1.65 and its highest was $51.75 in the past 12 months.
What is Silexion Therapeutics Corp’s market cap?
Silexion Therapeutics Corp’s market cap is $6.60M.
When is Silexion Therapeutics Corp’s upcoming earnings report date?
Silexion Therapeutics Corp’s upcoming earnings report date is Mar 24, 2026 which is in 74 days.
How were Silexion Therapeutics Corp’s earnings last quarter?
Silexion Therapeutics Corp released its earnings results on Nov 12, 2025. The company reported -$2.88 earnings per share for the quarter, beating the consensus estimate of -$3.4 by $0.52.
Is Silexion Therapeutics Corp overvalued?
According to Wall Street analysts Silexion Therapeutics Corp’s price is currently Undervalued.
Does Silexion Therapeutics Corp pay dividends?
Silexion Therapeutics Corp does not currently pay dividends.
What is Silexion Therapeutics Corp’s EPS estimate?
Silexion Therapeutics Corp’s EPS estimate is -1.12.
How many shares outstanding does Silexion Therapeutics Corp have?
Silexion Therapeutics Corp has 3,126,642 shares outstanding.
What happened to Silexion Therapeutics Corp’s price movement after its last earnings report?
Silexion Therapeutics Corp reported an EPS of -$2.88 in its last earnings report, beating expectations of -$3.4. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Silexion Therapeutics Corp?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics Corp
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
$9.00
▲(307.24% Upside)